<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="29097">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727933</url>
  </required_header>
  <id_info>
    <org_study_id>AI444-335</org_study_id>
    <nct_id>NCT02727933</nct_id>
  </id_info>
  <brief_title>Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea</brief_title>
  <official_title>Postmarketing Surveillance of the Safety and Effectiveness of Daclatasvir and Asunaprevir for the Treatment of Chronic HCV Genotype 1B Infection in the Routine Clinical Practice in Korea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to describe the safety of the combination of Daklinza
      (daclatasvir) and Sunvepra (asunaprevir) when used for the treatment of chronic hepatitis C
      (CHC) genotype 1b patients in real-life conditions when used according to its registered
      indications.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Years</target_duration>
  <primary_outcome>
    <measure>Frequency of expected and unexpected adverse reactions (AEs) and serious adverse events (SAEs)/reactions. These include laboratory abnormalities</measure>
    <time_frame>6 months to 5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence proportion of AEs leading to discontinuation of study therapy</measure>
    <time_frame>6 months to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence rate of AEs leading to discontinuation of study therapy</measure>
    <time_frame>6 months to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Timing of laboratory abnormalities by toxicity grade</measure>
    <time_frame>6 months to 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HCV (Hepatitis C Virus) RNA (Ribonucleic acid)&lt; lower limit of quantification (LLQ) target not detected and detected</measure>
    <time_frame>4 Weeks to 24 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The sustained virologic response (SVR12) of the combination of Daklinza and Sunvepra (HCV RNA &lt; lower limit of quantification [LLQ] target not detected and detected (HCV RNA &lt; 25 IU/mL)</measure>
    <time_frame>24 Weeks to 36 Weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1316</enrollment>
  <condition>Hepatitis C</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Primary Care Clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with CHC genotype 1b and compensated liver disease, including cirrhotic
             patients

          -  Eligible for treatment with Daklinza and Sunvepra as indicated in the locally
             approved prescribing information.

        Exclusion Criteria:

          -  Off-label use of Daklinza and Sunvepra

          -  Patients with a contraindication for the use of Daklinza and Sunvepra as described in
             the locally approved prescribing information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>March 29, 2017</lastchanged_date>
  <firstreceived_date>March 18, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
